Open-label acamprosate treatment in persons with FXS has been shown to modulate amyloid precursor protein (APP) and brain-derived neurotrophic factor (BDNF), both upstream regulators of ERK1/2 signaling [40–44]. Here, MAPK3 is linked to fragile X syndrome.